TAZ upregulates MIR-224 to inhibit oxidative stress response in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Oxidative stress in the bone marrow niche drives multiple myeloma (MM) progression and drug resistance.
• The Hippo pathway is linked to miRNA biogenesis and oxidative stress in solid tumors, with potential interrelations in various cancers.
• Previous research indicated TAZ acts as a tumor suppressor in MM, but its role in oxidative stress within this context was unexplored.

Purpose of the Study:

• To investigate the function of TAZ in the response of myeloma cells to bone marrow oxidative stress.
• To determine if TAZ is associated with an oxidative stress phenotype and a specific miRNA signature in MM.

Main Methods:

• Utilized human myeloma cell lines and clinical samples.
• Analyzed the molecular mechanisms involving TAZ, miR-224, and the NRF2 antioxidant pathway.
• Assessed the impact of TAZ and miR-224 expression on myeloma cell sensitivity to oxidative stress and therapeutic agents.

Main Results:

• TAZ enhances myeloma cell sensitivity to oxidative stress and drug-induced cytotoxicity by upregulating miR-224, which suppresses the NRF2 antioxidant program.
• Low TAZ protein expression correlates with an oxidative stress-resistant phenotype in MM.
• Overexpression of miR-224 in low-TAZ myeloma cells inhibits cell growth and increases sensitivity to anti-myeloma drugs.

Conclusions:

• TAZ plays a role in the oxidative stress response in MM through the miR-224-NRF2 pathway.
• miR-224 presents a potential therapeutic target for modulating TAZ expression and improving MM treatment efficacy.